Evotec earns milestones from Boehringer

Evotec has garnered $6 million in milestones payments as part of its drug discovery deal with Boehringer Ingelheim. One milestone was achieved for the start of lead optimization for a specific target. The second was the result of a separate program for the selection of a compound by Boehringer Ingelheim for preclinical development. Evotec release